Durable Response to Combined Osimertinib and Pralsetinib Treatment for Osimertinib Resistance Due to Novel Intergenic <i>ANK3-RET</i> Fusion in <i>EGFR</i>-Mutated Non-Small-Cell Lung Cancer.

Urbanska, Edyta M; Sørensen, Jens B; Melchior, Linea C; Costa, Junia C; Santoni-Rugiu, Eric

Durable Response to Combined Osimertinib and Pralsetinib Treatment for Osimertinib Resistance Due to Novel Intergenic ANK3-RET Fusion in EGFR-Mutated Non-Small-Cell Lung Cancer.

Urbanska, Edyta M; Sørensen, Jens B; Melchior, Linea C; Costa, Junia C; Santoni-Rugiu, Eric.

Afiliação

Urbanska EM; Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
Sørensen JB; Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
Melchior LC; Department of Pathology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
Costa JC; Department of Radiology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
Santoni-Rugiu E; Department of Pathology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.

JCO Precis Oncol ; 6: e2200040, 2022 07.

Article em En | MEDLINE | ID: mdl-35797511

Assuntos

Carcinoma Pulmonar de Células não Pequenas; Neoplasias Pulmonares; Acrilamidas; Compostos de Anilina; Anquirinas; Carcinoma Pulmonar de Células não Pequenas/tratamento farmacológico; Receptores ErbB/genética; Humanos; Indóis; Neoplasias Pulmonares/tratamento farmacológico; Proteínas Proto-Oncogênicas c-ret; Pirazóis; Piridinas; Pirimidinas

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma Pulmonar de Células não Pequenas / Neoplasias Pulmonares Limite: Humans Idioma: En Revista: JCO Precis Oncol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Dinamarca

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google